Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association

CAMBRIDGE, Mass.--()--Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and for orphan indications, today announced that data from the Company’s Phase 1 trial of its lead product candidate, RA101495, a synthetic macrocyclic peptide inhibitor of complement C5 for paroxysmal nocturnal hemoglobinuria (PNH), will be presented at the 21st Congress of the European Hematology Association (EHA) from June 9-12, 2016 in Copenhagen, Denmark.

Details of the poster presentation are as follows:

Title: A Phase 1 Single-ascending-dose Clinical Study of RA101495, a Subcutaneously Administered Synthetic Macrocyclic Peptide Inhibitor of Complement C5 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Session Title: Bone marrow failure syndromes incl. PNH - Biology (Poster)
Date/Time: Saturday, June 11, 5:30 - 7:00 PM Local Time
Location: Poster area (Hall H)
Abstract Code: P632

Details of the E-poster presentation are as follows:

Title: A Phase 1 Multiple-dose Clinical Study of RA101495, a Subcutaneously Administered Synthetic Macrocyclic Peptide Inhibitor of Complement C5 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Topic: Bone marrow failure syndromes incl. PNH - Clinical
Date/Time: Friday, June 10, 9:30 AM Local Time - Sunday, June 12, 11:00 AM Local Time
Location: Poster area (Hall H)
Abstract Code: LB2249

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and for orphan indications. The Company utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. Derived from its proprietary Extreme Diversity™ peptide chemistry platform, RA101495 is a macrocyclic peptide inhibitor of complement C5, and is currently in Phase 1 development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). For more information, please visit: www.rapharma.com.

Contacts

Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com

Contacts

Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com